SCHEMBL23123784

SCHEMBL23123784

CC1(C)CN(c2cccc(N)c2N)CCO1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
FFAR2 O15552 6/20 0.42
LATS1 O95835 1/20 0.40
PRKDC P78527 2/20 0.38
PIK3CA P42336 3/20 0.38
MTOR P42345 3/20 0.38
LRRK2 Q5S007 1/20 0.37
ADRA2C P18825 1/20 0.37
GAK O14976 1/20 0.36
KEAP1 Q14145 1/20 0.35
MAP3K12 Q12852 1/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
PDE10A Q9Y233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29745079 0.81 FFAR2 (0.39) C5AR1FFAR2LATS1PRKDCPIK3CA
SCHEMBL23123675 0.81 FFAR2 (0.39) C5AR1FFAR2LATS1PRKDCPIK3CA
SCHEMBL31248708 0.76 LGMN (0.51) ADRA2CKEAP1MEN1USP2GAA
SCHEMBL904453 0.76 LGMN (0.51) ADRA2CKEAP1MEN1USP2GAA
SCHEMBL17381856 0.76 FFAR2 (0.47) C5AR1FFAR2LATS1PRKDCPIK3CA
SCHEMBL16702866 0.75 LATS1 (0.54) C5AR1FFAR2LATS1PRKDCPIK3CA
SCHEMBL13724322 0.73 MAPT (0.54) C5AR1FFAR2LATS1PRKDCPIK3CA
SCHEMBL22163203 0.73 PRKDC (0.46) C5AR1FFAR2LATS1PRKDCPIK3CA
SCHEMBL6624674 0.72 MAPT (0.46) FFAR2LATS1PRKDCPIK3CAMTOR
SCHEMBL18436319 0.71 LMNA (0.52) C5AR1FFAR2LATS1PRKDCPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380319-A1 SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 US disclosed
EP-4031532-A1 SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
CN-114787136-A Substituted benzimidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed
WO-2021055591-A1 SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL-BioTech Investments, Inc. (US) 2021-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380319-A1 SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GAA, GBA1, CLN6 C5AR1 4522/4885FFAR2 2592/4885LATS1 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.